IRVINE, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--ALPHAEON Corporation and NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that they have formed a partnership that will add NovaBay’s breakthrough Avenova™ to the products that ALPHAEON makes available to patients and doctors.
Under terms of the agreement, Avenova will now be available for purchase on the ShoutMD® Store, the first social commerce store for lifestyle healthcare products. On ShoutMD, member physicians will now be able to learn about Avenova, rate, review and purchase it for their patients.
Avenova product information is now available on the ShoutMD website and will be made available to purchase by their member doctors for online transactions and reward points beginning in early October 2015.
“This partnership will expand our commercial reach, enabling us to offer Avenova to more ophthalmologists throughout the U.S.,” said Ron Najafi, Ph.D., President and CEO of NovaBay. “We believe it will increase revenues for NovaBay, but more importantly, it means that more patients suffering from common, chronic and often-painful eye conditions like blepharitis will finally be able to find relief.”
Avenova is the only lid hygiene product that contains Neutrox, NovaBay’s proprietary pure hypochlorous acid, which mimics a naturally occurring substance produced by white blood cells to fight microbial invaders. Lab tests show that NovaBay’s proprietary formulation of pure hypochlorous acid is effective in solution both at killing microbes and at neutralizing bacterial enzymes and toxins. Those properties enable Avenova to help in managing the symptoms associated with blepharitis and other common eye conditions like meibomian gland dysfunction. Indeed, both patients and doctors report that a regimen of daily lid hygiene using Avenova has been remarkably successful in managing those conditions.
About ALPHAEON
ALPHAEON Corporation is a social commerce
company with the goal of transforming self-pay healthcare by bringing to
market highly innovative products and services to promote consumer
wellness, beauty and performance. The company works in partnership with
board certified physicians ensuring access to leading advancements in
lifestyle healthcare. For more information, please visit www.alphaeon.com.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics
NovaBay
Pharmaceuticals is a biopharmaceutical company focusing on
commercializing and developing its non-antibiotic anti-infective
products to address the unmet therapeutic needs of the global, topical
eye care market with its two distinct product categories: the NEUTROX™
Family of Products, cleared by the US FDA as a 510(k) medical device;
the NEUTROX™ Family of Products includes NEUTROPHASE®
for wound care, AVENOVA™ for the eye care market
and CELLERX™ for the cosmetic surgery and
aesthetic dermatology market; and its AGANOCIDE® compounds,
led by AURICLOSENE™ which is in development as a new
drug in urology and dermatology.
NovaBay has partnerships in the U.S. and around the world with PBE, Inc. (U.S.), IHT, Inc. (U.S.), Galderma (France), Virbac (France), China Pioneer Pharma (China and Southeast Asia), Shin Poong Pharmaceuticals (South Korea), Biopharm (North African and the Middle East), Sarmedic Ltd (Israel), Ophthalmic Instrument Company (New Zealand) and Alpha Pharma LLC (the Ukraine).
In June 2015 NovaBay announced FDA clearance of intelli-Case™, an innovative, easy-to-use device for safely disinfecting soft and rigid gas permeable (RGP) contact lenses with hydrogen peroxide.
Forward-looking Statements:
This press release contains "forward-looking statements." Forward-looking statements are not guarantees of future performance, are based on assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control. Forward-looking statements, such as those regarding potential future product revenue, cannot be accurately predicted or quantified and consequently, actual results may differ materially from those expressed. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Stay informed on NovaBay's progress:
Download
our Mobile InvestorApp from the Apple
Store or Google
Play
Like us on Facebook
Follow
us on Twitter
Connect
with NovaBay on LinkedIn
Join
us on Google+
Visit
NovaBay's
Website
